Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | LMNA | P02545 | 6/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | FTO | Q9C0B1 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.52 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.52 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29349570 | 1.00 | MAPT (0.66) | MAPTLMNAMEN1KMT2AHTT | |
| SCHEMBL10145450 | 0.93 | MAPT (0.58) | MAPTLMNAMEN1KMT2AHTT | |
| SCHEMBL18184153 | 0.90 | MAPT (0.58) | MAPTLMNAMEN1KMT2AHTT | |
| SCHEMBL10100294 | 0.88 | MAPT (0.53) | MAPTLMNAMEN1KMT2AHTT | |
| SCHEMBL10100273 | 0.88 | MAPT (0.53) | MAPTLMNAMEN1KMT2AHTT | |
| SCHEMBL14005748 | 0.88 | MAPT (0.54) | MAPTLMNAMEN1KMT2AHTT | |
| SCHEMBL18184154 | 0.88 | MAPT (0.55) | MAPTLMNAMEN1KMT2AHTT | |
| SCHEMBL13914140 | 0.87 | MAPT (0.67) | MAPTLMNAMEN1KMT2AHTT | |
| SCHEMBL13620743 | 0.87 | FTO (0.57) | MAPTLMNAMEN1KMT2AHTT | |
| SCHEMBL30378455 | 0.86 | MAPT (0.66) | MAPTLMNAMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4647532-A | Method for determination of hydrogen peroxide by chemiluminescence analysis | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1987-03-03 | — | — | US | claimed |
| CN-115708874-B | Matrine-loaded PEGylated two-dimensional boron alkene nanosheet as well as preparation method and application thereof | 广州中医药大学(广州中医药研究院) | 2024-10-29 | — | — | CN | disclosed |
| CN-117599214-A | Cisplatin diagnosis and treatment probe targeting carbonic anhydrase and preparation method and application thereof | 南京大学 | 2024-02-27 | — | — | CN | disclosed |
| EP-3522870-B1 | ULTRALOW-POWER NEAR INFRARED LAMP LIGHT OPERABLE TARGETED ORGANIC NANOPARTICLE PHOTODYNAMIC THERAPY | UNIV MASSACHUSETTS (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-2920223-B1 | MOISTURE INDICATING HYDROPHILIC POLYURETHANE | MOELNLYCKE HEALTH CARE AB (SE) | 2023-07-12 | — | — | EP | disclosed |
| CN-115368579-B | Preparation method and application of nano-enzyme with manganese porphyrin as metal organic framework | 南京大学 | 2023-06-27 | — | — | CN | disclosed |
| EP-4193848-A1 | COMPOSITION FOR USE IN THE TREATMENT OF ERECTILE DYSFUNCTION | Anvest Group S.r.l. (IT) | 2023-06-14 | — | — | EP | disclosed |
| US-20230118467-A1 | COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L | SYMRISE AG (DE) | 2023-04-20 | — | — | US | disclosed |
| CN-115708874-A | Matrine-loaded polyethylene glycol two-dimensional borolene nanosheet and preparation method and application thereof | 广州中医药大学(广州中医药研究院) | 2023-02-24 | — | — | CN | disclosed |
| EP-4114353-A1 | COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L | Symrise AG (DE) | 2023-01-11 | — | — | EP | disclosed |
| WO-2007144530-A2 | FREE-RADICAL-SCAVENGER COSMETIC COMPOSITION | LVMH RECHERCHE (FR) | 2007-12-21 | — | — | WO | disclosed |
| EP-1608623-A4 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | NEWSOUTH INNOVATIONS PTY LTD (AU) | 2007-07-18 | — | — | EP | disclosed |
| US-20060252798-A1 | Metal ion chelators and therapeutic use thereof | RICHARDSON, DESI (AU) | 2006-11-09 | — | — | US | disclosed |
| EP-1608623-A1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | UNISEARCH LIMITED (AU) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004069801-A1 | METAL ION CHELATORS AND THERAPEUTIC USE THEREOF | UNISEARCH LIMITED (AU) | 2004-08-19 | — | — | WO | disclosed |
| EP-0723778-B1 | Composition for induction of apoptosis comprising a factor increasing the intracellular level of methional or malondialdehyde | INT DE CENTRE (FR) | 2000-04-05 | — | — | EP | disclosed |
| US-5744499-A | Apoptosis-modulating factors influencing the intracellular concentration of methional/malondialdehyde | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) | 1998-04-28 | — | — | US | disclosed |
| EP-0723778-A1 | Composition for modulation of apoptosis comprising a factor influencing the intracellular level of methional or malondialdehyde | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1996-07-31 | — | — | EP | disclosed |
| WO-1996020701-A1 | APOPTOSIS-MODULATING COMPOSITION COMPRISING A FACTOR AFFECTING THE INTRACELLULAR RATE OF METHIONAL OR MALONDIALDEHYDE | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (C.I.R.D. GALDERMA) (FR) | 1996-07-11 | — | — | WO | disclosed |
| US-4647532-A | Method for determination of hydrogen peroxide by chemiluminescence analysis | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 1987-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252798-A1 | Metal ion chelators and therapeutic use thereof | SLC40A1, SLC30A6, SLC39A3 | MAPT 3817/4885LMNA 4715/4885MEN1 1305/4885 |
| US-20230118467-A1 | COSMETIC OR PHARMACEUTICAL USE OF AVENANTHRAMIDE L | TACR1, NPSR1, TACR2 | MAPT 991/4885LMNA 2206/4885MEN1 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.